Stock analysts at Cantor Fitzgerald assumed coverage on shares of Spero Therapeutics (NASDAQ:SPRO) in a report issued on Thursday. The firm set an “overweight” rating and a $27.00 price target on the stock. Cantor Fitzgerald’s price target would suggest a potential upside of 125.56% from the company’s current price.
The analysts wrote, “Differentiated pipeline addresses large unmet needs in infectious disease. Spero has three development programs that target multibillion-dollar commercial opportunities. The company’s drugs focus on unmet needs inside and outside the hospital setting. Spero plans to commercialize its products using an accelerated path to market, saving investors time and money. The company’s three leading drugs: 1) SPR994/oral carbapenem, which could be the first new oral therapy for cUTI in 21 years. Unlike competing drugs, SPR994 will be covered outside the hospital formulary, where it will not compete with generics and be part of the bundle. The drug is being developed for UTI, but could also be used for IAI, blood stream infections, and CAP; 2) SPR741 and SPR206/IV potentiators address major unmet needs in the hospital setting and expand the utility of existing antibiotics; and, 3) the SPR720/NTM program is a novel oral bacterial gyrase inhibitor designed to treat a rare lung infection.””
A number of other equities analysts also recently weighed in on SPRO. Oppenheimer set a $30.00 target price on shares of Spero Therapeutics and gave the stock a “buy” rating in a research note on Thursday, January 11th. Zacks Investment Research downgraded shares of Spero Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, January 31st. ValuEngine raised shares of Spero Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Friday, February 2nd. Cowen assumed coverage on shares of Spero Therapeutics in a research note on Monday, November 27th. They set an “outperform” rating for the company. Finally, Stifel Nicolaus assumed coverage on shares of Spero Therapeutics in a research note on Monday, November 27th. They set a “buy” rating and a $26.00 target price for the company. One research analyst has rated the stock with a sell rating, two have issued a hold rating and four have given a buy rating to the stock. Spero Therapeutics has an average rating of “Hold” and an average target price of $24.25.
Spero Therapeutics (NASDAQ:SPRO) last announced its earnings results on Thursday, December 14th. The company reported ($36.02) earnings per share for the quarter, missing analysts’ consensus estimates of ($2.43) by ($33.59). The company had revenue of $0.60 million for the quarter, compared to analyst estimates of $0.20 million. analysts expect that Spero Therapeutics will post -8.52 EPS for the current fiscal year.
Institutional investors and hedge funds have recently bought and sold shares of the business. Dean Capital Investments Management LLC bought a new stake in Spero Therapeutics in the fourth quarter valued at $118,000. California Public Employees Retirement System bought a new stake in Spero Therapeutics in the fourth quarter valued at $294,000. Finally, Atlas Venture Associates IX LLC bought a new stake in Spero Therapeutics in the fourth quarter valued at $16,179,000. 0.01% of the stock is owned by hedge funds and other institutional investors.
COPYRIGHT VIOLATION NOTICE: “Spero Therapeutics (SPRO) Earns Overweight Rating from Analysts at Cantor Fitzgerald” was published by American Banking News and is the property of of American Banking News. If you are reading this story on another site, it was stolen and republished in violation of United States and international copyright and trademark legislation. The legal version of this story can be viewed at https://www.americanbankingnews.com/2018/02/08/spero-therapeutics-spro-earns-overweight-rating-from-analysts-at-cantor-fitzgerald.html.
Spero Therapeutics Company Profile
Spero Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on identifying, developing and commercializing novel treatments for MDR bacterial infections. The Company is developing a portfolio of novel product candidates, including SPR994, Potentiator Platform (SPR741 and SPR206), and SPR720.
Receive News & Ratings for Spero Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spero Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.